let’s talk



Degron News Media Report

Dr. Xiaobing Qian joins Degron Therapeutics as Chief Development Officer

Degron Therapeutics, In c. announced today that Xiaobing Qian, M.D., Ph.D., recently joined the company as Chief Development Officer and a member of the executive management team.

By Degron,  Feb. 7, 2023 

Degron Therapeutics Co-Founder is invited to speak at the TPD meeting in San Diego

Dr. Yong Cang, CSO and Co-Founder of Degron Therapeutics, who has dedicated his research to the TPD field for over 20 years, will attend this event as a speaker.

By Degron,  Dec. 6, 2022 

Degron Therapeutics Co-Founder Provides New Strategy for Molecular Glue in Tumor Immunotherapy

Research published in Cell Chemical Biology showed lenalidomide can enhance cancer-treating ability of PD-1 antibody

By Degron,  June 28, 2022,  

Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform

SAN DIEGO, Calif., and SHANGHAI, China, June 9, 2022 - Degron Therapeutics (“Degron”), a biotechnology company developing a new class of small-molecule medicines that target previously undruggable targets, today announce...

By Degron,  June 09,2022 

Degron Therapeutics Had an Exclusive Interview with CCTV2 "Economy 30 Minutes" Program

At 8:00 p.m. on March 11, 2022, the prime-time program “Economy 30 Minutes” on CCTV2 broadcast a special report on the Shanghai Pudong Economic Development Zone and highlighted the innovation in life sciences of JLABS in...

By Degron,  March 11, 2022 

The Theme Activities of "Degron Date" Concluded Successfully

With lush greens and pleasant weather, Shanghai headed into the best March spring. Degron empoyees got together for a special "Degron Date", a series of activities to be held regularly,with different themes com...

By Degron, March 10, 2022 

Molecular Glue Degraders,a New Dawn Since PROTACs

Yong Cang, professor of ShanghaiTech University and co-founder of Degron Therapeutics

By Yong Cang,  August 18, 2020,